Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)

v3.22.0.1
Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Net earnings, including noncontrolling interest $ 72,059 $ 68,981 $ 46,144 $ 33,395 $ 141,040 $ 79,538
Net earnings (loss) attributable to noncontrolling interest (8,114)   (130)   (8,748) (130)
Net earnings attributable to Bio-Techne 80,173   46,274   149,788 79,668
Income allocated to participating securities (34)   (37)   (70) (50)
Income available to common shareholders $ 80,139   $ 46,237   $ 149,718 $ 79,618
Basic (in shares) 39,310   38,691   39,202 38,614
Basic (in dollars per share) $ 2.04   $ 1.20   $ 3.82 $ 2.06
Income allocated to participating securities $ (34)   $ (37)   $ (70) $ (50)
Income available to common shareholders $ 80,139   $ 46,237   $ 149,718 $ 79,618
Dilutive effect of stock options and restricted stock units (in shares) 1,897   1,566   1,957 1,521
Diluted (in shares) 41,207   40,257   41,159 40,135
Diluted (in dollars per share) $ 1.94   $ 1.15   $ 3.64 $ 1.98